[Recombinant antibodies for medical protection against bioterrorism agents: the example of anthrax].

Abstract

Recombinant antibodies are a highly successful class of therapeutic molecules, they are well adapted for use against bio-weapons (BW) as they act immediately, are often synergistic with other therapeutic molecules, have a long half-life and are well tolerated. Anthrax is regarded at high risk of being used as BW, and its pathogenic properties depend on toxins, which might be neutralized by antibodies. These toxins are made of three different types of sub-units (PA, LF, EF). Several anti-PA have been developed, including an original approach by our team. We have developed an anti-LF, as recommended by experts. Our anti-PA antibody, and to a lesser extend our anti-LF antibody, will be presented here.

• Authors: Philippe Thullier, Thibault Pelat, Jean-Charles Paucod, Dominique Vidal
• Journal: Biologie aujourd'hui (Biol Aujourdhui) Vol. 204 Issue 1 Pg. 81-6 ( 2010) ISSN: 2105-0678 [Print] France
• Vernacular Title: Intérêt des anticorps recombinants dans la protection médicale contre les agents du bioterrorisme: l'exemple de la maladie du charbon.
• PMID: 20950579 (Publication Type: English Abstract, Journal Article, Review)
• Copyright: © Société de Biologie, 2010.

Chemical References

• Antibodies
• Antibodies, Bacterial
• Recombinant Proteins

Topics

• Animals
• Anthrax (immunology, veterinary)
• Antibodies (genetics, therapeutic use)
• Antibodies, Bacterial (genetics, therapeutic use)
• Bioterrorism
• Humans
• Mice
• Neutralization Tests
• Recombinant Proteins (therapeutic use)